PGEN vs. ATAI, SBTX, NKTX, AVIR, NATR, VTYX, VRCA, KMDA, ORGO, and CRMD
Should you be buying Precigen stock or one of its competitors? The main competitors of Precigen include Atai Life Sciences (ATAI), Silverback Therapeutics (SBTX), Nkarta (NKTX), Atea Pharmaceuticals (AVIR), Nature's Sunshine Products (NATR), Ventyx Biosciences (VTYX), Verrica Pharmaceuticals (VRCA), Kamada (KMDA), Organogenesis (ORGO), and CorMedix (CRMD). These companies are all part of the "pharmaceutical preparations" industry.
Atai Life Sciences (NASDAQ:ATAI) and Precigen (NASDAQ:PGEN) are both small-cap medical companies, but which is the superior business? We will compare the two companies based on the strength of their valuation, analyst recommendations, risk, media sentiment, dividends, earnings, institutional ownership, community ranking and profitability.
Atai Life Sciences has a beta of 0.92, suggesting that its share price is 8% less volatile than the S&P 500. Comparatively, Precigen has a beta of 1.77, suggesting that its share price is 77% more volatile than the S&P 500.
28.4% of Atai Life Sciences shares are held by institutional investors. Comparatively, 33.5% of Precigen shares are held by institutional investors. 30.0% of Atai Life Sciences shares are held by insiders. Comparatively, 41.7% of Precigen shares are held by insiders. Strong institutional ownership is an indication that endowments, hedge funds and large money managers believe a stock is poised for long-term growth.
In the previous week, Precigen had 1 more articles in the media than Atai Life Sciences. MarketBeat recorded 2 mentions for Precigen and 1 mentions for Atai Life Sciences. Atai Life Sciences' average media sentiment score of 0.00 beat Precigen's score of -0.30 indicating that Precigen is being referred to more favorably in the news media.
Precigen received 100 more outperform votes than Atai Life Sciences when rated by MarketBeat users. Likewise, 67.03% of users gave Precigen an outperform vote while only 65.92% of users gave Atai Life Sciences an outperform vote.
Precigen has a net margin of -1,540.63% compared to Precigen's net margin of -12,810.51%. Precigen's return on equity of -45.08% beat Atai Life Sciences' return on equity.
Atai Life Sciences currently has a consensus target price of $10.50, indicating a potential upside of 412.20%. Precigen has a consensus target price of $10.00, indicating a potential upside of 675.19%. Given Atai Life Sciences' higher probable upside, analysts clearly believe Precigen is more favorable than Atai Life Sciences.
Atai Life Sciences has higher earnings, but lower revenue than Precigen. Atai Life Sciences is trading at a lower price-to-earnings ratio than Precigen, indicating that it is currently the more affordable of the two stocks.
Summary
Precigen beats Atai Life Sciences on 11 of the 18 factors compared between the two stocks.
Get Precigen News Delivered to You Automatically
Sign up to receive the latest news and ratings for PGEN and its competitors with MarketBeat's FREE daily newsletter.
This chart shows the number of new MarketBeat users adding PGEN and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period.
This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.
Precigen Competitors List
Related Companies and Tools
